Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589979 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT00589979: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00589979 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00589979, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
Patients with knee pain due to Osteoarthritis (OA) experiencing sub-optimal pain relief from their current analgesic regimen will participate in a pilot clinical trial to evaluate the effectiveness and tolerability of the Lidoderm Patch compared with placebo in treating knee pain from OA.
Interventions
- DRUG Placebo Patch
- DRUG Lidoderm (Lidocaine 5% Patch)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00589979
The ClinicalTrials.gov registry entry for NCT00589979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Patch is the first listed.
NCT00589979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00589979 about?
NCT00589979 is a clinical study titled "Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee". Patients with knee pain due to Osteoarthritis (OA) experiencing sub-optimal pain relief from their current analgesic regimen will participate in a pilot clinical trial to evaluate the effectiveness and tolerability of the Lidoderm Patch compared with placebo in treating knee pain from OA.
What is the current status of trial NCT00589979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2007-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00589979?
The interventions under investigation include: Placebo Patch (DRUG), Lidoderm (Lidocaine 5% Patch) (DRUG).
Who is sponsoring clinical trial NCT00589979?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.